Try our mobile app

General information

Country: UNITED STATES

Sector: Medical Devices

Abbott Laboratories discovers, develops, manufactures, and sells a broad and diversified line of health care products and services. The Company"s products include pharmaceuticals, nutritional, diagnostics, and vascular products. Abbott markets its products worldwide through affiliates and distributors.
Website: abbott.com


  • Good financial results growth rate 11.0% (average between last period year over year growth for revenue and EBITDA), there is acceleration compared to average historical growth rates (-4.0%)
  • Dividend yield for the last twelve months 1.7%
  • Free cash flow yield 0.6% (LTM)
  • Share price is 47.8% higher than minimum and 4.9% lower than maximum for the last 3 years
  • The company is overvalued by EV / LTM EBITDA multiple compared to target level (28.3x vs
    )
  • Fundamental value created in LTM (estimate)
  • For the last 3 months insiders sold company shares on $12.6 mln (-0.005% of cap.)

Key Financials (Download financials)

Ticker: ABT
Share price, USD:  (+0.3%)133.32
year average price 118.92  


year start price 104.27 2024-06-06

min close price 100.07 2024-07-18

max close price 140.22 2025-03-03

current price 133.50 2025-06-05
Common stocks: 1 746 881 140

Dividend Yield:  1.7%
FCF Yield LTM: 0.6%
EV / LTM EBITDA: 28.3x
EV / EBITDA annualized: 29.4x
Last revenue growth (y/y):  +4.0%
Last growth of EBITDA (y/y):  +18.0%
Historical revenue growth:  -1.2%
Historical growth of EBITDA:  -6.7%
Target EV / EBITDA (hist percentile):
Express share price potential:
Fundamental value created in LTM:
EV / LTM EBITDA mutiple calculation
Market Cap ($m): 232 894
Net Debt ($m): 6 667
EV (Enterprise Value): 239 561
EBITDA LTM ($m): 8 475
EV / LTM EBITDA: 28.3x
Price to Book: 5.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / EBITDA

Potential dynamics

News


2025-06-05zacks.com

Is Abbott (ABT) a Buy as Wall Street Analysts Look Optimistic?

2025-06-04zacks.com

Abbott (ABT) Stock Drops Despite Market Gains: Important Facts to Note

2025-05-29zacks.com

Abbott (ABT) Rises Higher Than Market: Key Facts

2025-05-27seekingalpha.com

Abbott Laboratories: Why Wall Street's Skepticism Misses The Real Story

2025-05-23247wallst.com

4 Dividend Aristocrats Are Absolutely Crushing the S&P 500 in 2025

2025-05-23fool.com

2 Dividend Stocks to Buy With $500 and Hold Forever

2025-05-20247wallst.com

Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys

2025-05-20zacks.com

Is It Worth Investing in Abbott (ABT) Based on Wall Street's Bullish Views?

2025-05-19zacks.com

Abbott Reveals Positive Outcome From REFLECT Studies, Stock Climbs

2025-05-03fool.com

2 Stocks, 2 Decades, $200. Is This the Long-Term Dividend Play for Your Portfolio?
More information for subscribed users:
detailed calculation of
Potential and Created Value,
website traffic data